Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 140.46 0.16% 0.22
ALXN closed up 0.16 percent on Thursday, October 19, 2017, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Oct 26

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Flat Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Oct 19 Crossed Above 50 DMA Bullish 0.00%
Oct 19 Bollinger Band Squeeze Range Contraction 0.00%
Oct 18 Fell Below 50 DMA Bearish 0.16%
Oct 18 Bollinger Band Squeeze Range Contraction 0.16%
Oct 18 New Uptrend Bullish 0.16%

Older signals for ALXN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 149.34
52 Week Low 96.18
Average Volume 1,382,680
200-Day Moving Average 128.088
50-Day Moving Average 140.451
20-Day Moving Average 141.3485
10-Day Moving Average 141.428
Average True Range 3.0468
ADX 25.4
+DI 22.15
-DI 13.24
Chandelier Exit (Long, 3 ATRs ) 135.7696
Chandelier Exit (Short, 3 ATRs ) 145.9604
Upper Bollinger Band 144.3289
Lower Bollinger Band 138.3681
Percent B (%b) 0.35
BandWidth 4.217095
MACD Line 0.085
MACD Signal Line 0.3426
MACD Histogram -0.2576
Fundamentals Value
Market Cap 31.35 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 60.81
Price-to-Sales 9.41
Price-to-Book 3.63
PEG Ratio 1.36
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 143.88
Resistance 3 (R3) 143.78 142.53 143.31
Resistance 2 (R2) 142.53 141.66 142.59 143.12
Resistance 1 (R1) 141.50 141.12 142.02 141.60 142.93
Pivot Point 140.25 140.25 140.51 140.31 140.25
Support 1 (S1) 139.22 139.38 139.74 139.32 137.99
Support 2 (S2) 137.97 138.84 138.03 137.80
Support 3 (S3) 136.94 137.97 137.61
Support 4 (S4) 137.04